Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 15

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 1
Chunk 15
---
 prices are publicly available would
be utilized in the calculation.

Expected
term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of
the vesting term plus contract term. The risk-free rate is based on the 5-year U.S. Treasury yield curve in effect at the time of grant.
The Company recognizes forfeitures as they occur.

The
following is option activity during the six months ended June 30, 2025.

 Schedule
of option activity

    Number of Shares  
    Weighted Average Exercise Price Per Share  
    Weighted Average Remaining Contractual Life (Years)  
    Aggregate Intrinsic Value 
  
    Outstanding as December 31, 2024 
     2,352,670  
    $5.02  
     9.6  
    $- 
  
    Options granted 
     2,050,000  
    $2.12  
     -  
    $- 
  
    Expired 
     (12,500) 
    $5.02  
     -  
    $- 
  
    Forfeitures 
     (150,000) 
    $5.02  
     -  
    $- 
  
    Outstanding as June 30, 2025 
     4,240,170  
    $3.62  
     9.4  
    $- 
  
    Exercisable, June 30, 2025 
     4,073,920  
    $3.61  
     9.4  
    $- 

    12

TELOMIR
PHARMACEUTICALS, INC.

NOTES
TO CONDENSED FINANCIAL STATEMENTS

JUNE
30, 2025

(Unaudited)

On May 13, 2025, the Company’s
CFO was granted 50,000 options to purchase Common Stock with an aggregate fair market value of approximately $0.1 million. The options
have a term of 10 years from the grant date. These options vest as follows: 50% vest on the 6 month anniversary of the date of grant and
the remaining 50% vest on the 12 month anniversary of the date of grant.

On May 27, 2025, the Company’s
CEO was granted 2,000